期刊文献+

急性髓系白血病NPM1基因突变检测的临床意义 被引量:3

Detection of NPM1 gene mutation in acute myeloid leukemia
原文传递
导出
摘要 目的 探讨初诊急性髓细胞白血病(acute myeloid leukemia,AML)患者NPM1基因突变发生率及其与染色体核型和FAB亚型之间的关系,并分析NPM1基因的突变类型.方法 选取2004至2010年中日友好医院血液科99例初诊AML患者.采集患者骨髓标本,采用聚合酶链反应(polymerase chain reaction,PCR)扩增基因组DNA,并采用变性聚丙烯酰胺凝胶电泳(polyacrylamide gel electrophoresis,PAGE)和毛细管电泳两种方法对AML患者NPM1基因突变进行检测.应用G显带方法对其中72例初诊AML患者进行细胞遗传学分析,同时对10例NPM1突变阳性患者进行直接测序分析.NPM1插入突变在各亚型患者中发生率的比较采用x2检验.变性PAGE和毛细管电泳两种方法检测NPM1基因突变发生率的比较采用McNemar检验.结果 毛细管电泳法与变性PAGE法检测AML患者NPM1基因插入突变发生率分别为15% (15/99)和11% (11/99),差异无统计学意义(x2 =2.25,P>0.05).NPM1插入突变在各亚型患者中发生率分别为:急性粒细胞白血病部分分化型(M2)(27%,8/30)、急性单核细胞白血病(M5)(32%,6/19)、红白血病(M6)(13%,1/8),差异无统计学意义(x2=1.06,P>0.05),其余亚型未检测到NPM1插入突变.49例AML异常核型患者的NPM1插入突变发生率为4% (2/49),23例正常核型患者的NPM1插入突变发生率为26% (6/23),差异有统计学意义(x2=5.61,P<0.05).10例NPM1基因插入突变均为A型突变(c.860_863 dupTCTG).突变导致NPM蛋白羧基末端读码框移,末尾7个氨基酸WQWRKSL被11个氨基酸CLAVEEVSLRK所代替.2例患者检测到内含子缺失突变,分别为IVS10-18_-15delCTTT和IVS10-17-15delTTT.结论 NPM1插入突变为AML患者常见基因改变,正常核型患者插入突变发生率高于异常核型患者.在NPM1基因内含子区发现2例缺失突变. Objective To analyze the frequency of NPM1 mutation in de novo acute myeloid leukemia (AML) patients and the relationship between NPM1 mutation and chromosome alterations,as well as FAB subgroups,and to analyze the mutation type.Methods A total of 99 de novo AML patients from 2004 to 2010 in China-Japan Friendship Hospital were studied.Genomic DNA was amplified by polymerase chain reaction (PCR),denaturing polyacrylamide gel electrophoresis (PAGE) and capillary electrophoresis were used to detect the mutation of NPM1 gene in 99 AML patients,and karyotyping was performed in 72 AML patients by G banding techniques.DNA sequences analysis of NPM1 mutation was performed on 10 patients.Chi-square test was used to compare the frequencies of NPM1 mutation among the different subgroups,and McNemar's test was used to compare the different rates between denaturing PAGE and capillary electrophoresis.Results The frequencies of NPM1 mutations were detected in 15% (15/99) of AML patients with capillary electrophoresis and 11% (11/99 ) with denaturing PAGE(x2 =2.25,P 〉0.05 ).The NPM1 was at different rates in M2(27%,8/30),M5(32%,6/19),M6( 13%,1/8),respectively (x2 =1.06,P 〉 0.05 ),and not detected in the other subgroups.NPM1 mutation in patients with normal karyotype(26% ) was more prevalent than patients with abnormal karyotype (4%) (x2 =5.61,P 〈 0.05)All of the 10 patients were of A type ( c.860_863dupTCTG).The C-terminal portion of the NPM protein by replacing the last seven amino acids(WQWRKSL) with 11 residues (CLAVEEVSLRK).Two intronic deletions were novel,one case was IVS10-18_-15delCTTT,the other was IVS10-17_-15delTTT.Conclusions NPM1 mutations represents a common genetic abnormality in AML patients,and NPM1 mutation in patients with normal karyotype is higher than patients with abnormal karyotype.Two new intronic deletion mutations are identified.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第1期27-31,共5页 Chinese Journal of Laboratory Medicine
关键词 白血病 髓样 急性 核蛋白质类 突变 电泳 毛细管 电泳 聚丙烯酰胺凝胶 Leukemia, myeloid, acute Nuclear proteins Mutation Electrophoresis,capillary Electrophoresis,polyacrylamide gel
  • 相关文献

参考文献12

  • 1Grisendi S,Mecucci C,Falini B,et al. Nucleophosmin and cancer.Nat Rev Cancer,2006,6:493-505.
  • 2Renneville A,Roumier C,Biggio V,et al. Cooperating gene mutations in acute myeloid leukemia:a review of the literature.Leukemia,2008,22:915-931.
  • 3张之南,沈悌.白血病诊断及疗效标准.3版.北京:科学出版社,2007:106-116.
  • 4Falini B,Mecucci C,Tiacci E,et al.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.N Engl J Med,2005,352:254-266.
  • 5Quentmeier H,Martelli MP,Dirks WG,et al.Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nuclephosmin.Leukemia,2005,19:1760-1767.
  • 6马亮,钟明华,廖军鲜,沈军,龙红,陈艳荣,马一盖.美国西南肿瘤组/东部肿瘤协作组染色体核型分组法与急性髓系白血病预后关系的研究[J].白血病.淋巴瘤,2010,19(1):20-22. 被引量:4
  • 7Falini B,Mecucci C,Tiacci E,et al.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.N Engl J Med,2005,352:254-266.
  • 8Li J,Wang L,Mamon H,et al.Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.Nat Med,2008,14:579-584.
  • 9Thiede C,Koch S,Creutzig E,et al.Prevalence and prognostic impact of NPM1 mutation in 1485 adult patients with acute myeloid leukemia(AML).Blood,2006,107:4011-4020.
  • 10Ruan GR,Li JL,Qin YZ,et al. Nuclephosmin mutations in Chinese adults with acute myelogenous leukemia.Ann Hematol,2009,88:159-166.

二级参考文献19

  • 1Mrzek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev, 2004, 18: 115-136.
  • 2Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oneology Group/Eastern Cooperative Oncology Group study. Blood, 2000, 96: 4075-4083.
  • 3张之南,沈悌.白血病诊断及疗效标准.3版.北京:科学出版社,2007:106-116.
  • 4Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogeneties on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood, 1998, 92: 2322-2333.
  • 5Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities arc predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia Group B(CALGB 8461). Blood, 2002, 100: 4325-4336.
  • 6Nguyen S, Leblanc T, Fenaux P, el al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup. Blood, 2002, 99: 3517-3523.
  • 7Richard FS, Konstanze D, Jurgen K, et al. Mutations and treatment outcome in cytngenetically normal acute myeloid leukemia. N Engl J Med, 2008, 355: 1909-1918.
  • 8Farag SS, Archer K J, Mrozek K, et al. Isolated trisomy of chromosomes 8,11,13and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from cancer and leukemia group B 8461. Int J Oncol, 2002, 21: 1041-1051.
  • 9Falini B,Mecucci C,Tiacci E,et al.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.N Engl J Med,2005,352:254-266.
  • 10Dohner K,Schlenk RF,Habdank M,et al.Mutant nucleophosmin(NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:interaction with other gene mutations.Blood,2005,106:3740-3746.

共引文献11

同被引文献49

  • 1卢瑞青,黄连生,童杰峰.急性单核细胞白血病合并胃癌1例报告[J].实用肿瘤杂志,2006,21(1):66-67. 被引量:4
  • 2段朝霞,杨林花.急性巨核细胞白血病合并肺癌一例[J].白血病.淋巴瘤,2007,16(1):18-18. 被引量:4
  • 3叶章群.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2011:274.
  • 4Bader MJ, Eisner B, Porpiglia F, et al. Contemporary management of ureteral stones[ J]. EurUrol, 2012, 61:764-772.
  • 5Mufioz JA, L6pez-Mesas M, Valiente M. Development and validation of a simple determination of urine metabolites oxalate, citrate, uric acid and creatinine) by capillary zone electrophoresis [J]. Talanta, 2010, 81:392-397.
  • 6Fares MC, Bini R, De Martino MC,et at. of acid preservatives in 24-hour urine for demand biochemical analytes in clinical Chim Acta, 2011, 412:2322-2325.
  • 7Implications for the use Barbas C, Garcia A, Saavedra L, et al. Urinary analysis of nephrolithiasis markers [J ]. J chromatogr B Analyt Technol Biomed Life Sci, 2002, 781:433-455.
  • 8Chauhan N, Narang J, Shweta, et al. Immobilization of barley oxalate oxidase onto gold-nanoparticle-porous CaCO3 microsphere hybrid for amperometric determination of oxalate in biological materials[J]. Clin Biochem, 2012, 45:253-258.
  • 9Maalouf NM, Adams Huet B, Pasch A, et al. Variability in urinary oxalate measurements between six international laboratories [ J]. Nephrol Dial Transplant, 2011, 26:3954-3959.
  • 10Mal TD, Hauser PC. Anion separations with pressure-assisted capillary electropboresis using a sequential injection analysis manifold and contactless conductivity detection [ J ]. Electrophoresis, 2011, 32:3000-3007.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部